Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Antiviral agent 35

Copy Product Info
😃Good
Catalog No. T79567Cas No. 2760972-52-7

Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].

Antiviral agent 35

Antiviral agent 35

Copy Product Info
😃Good
Catalog No. T79567Cas No. 2760972-52-7
Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mgInquiry8-10 weeks8-10 weeks
50 mgInquiry8-10 weeks8-10 weeks
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Resource Download

Product Introduction

Bioactivity
Description
Antiviral agent 35 (compound 4d) is a potent oral inhibitor of the influenza virus, targeting early stages of viral replication. It suppresses influenza-induced ROS accumulation, autophagy, apoptosis, and the inflammatory response mediated by the RIG-1 pathway in a mouse model of pulmonary infection. Its cytotoxicity is minimal in MDCK cells, with a CC50 greater than 800 μM, and it has anti-H1N1 (A/Weiss/43) activity with an EC50 of 2.28 μM [1].
In vitro
Antiviral agent 35 (compound 4d), at concentrations of 25 μM and 50 μM over a period of 24 to 72 hours, inhibits the replication of the influenza virus in MDCK cells [1].
In vivo
Antiviral agent 35 (compound 4d), administered to mice orally via gavage at dosages of 25, 50, and 100 mg/kg/day on days 2, 4, and 6 post-H1N1 infection, reduced pulmonary inflammation [1].
Chemical Properties
Molecular Weight418.47
FormulaC23H18N2O4S
Cas No.2760972-52-7
SmilesO=[N+](C(C=C1)=CC=C1S(N(C2=CC=CC3=C2C=CC=C3)CC4=CC=CC=C4)(=O)=O)[O-]
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Antiviral agent 35 | purchase Antiviral agent 35 | Antiviral agent 35 cost | order Antiviral agent 35 | Antiviral agent 35 chemical structure | Antiviral agent 35 in vivo | Antiviral agent 35 in vitro | Antiviral agent 35 formula | Antiviral agent 35 molecular weight